![Matthew Roden](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 2 M $ al 31/05/2026
El Dr. Matt M. Roden es director independiente de iTeos Therapeutics, Inc, socio ejecutivo de MPM Capital Inc, presidente y director general de Aktis Oncology, Inc, presidente y director de Celgene Corp. y presidente de Turmeric Acquisition Corp. Forma parte del Consejo de Administración de iTeos Therapeutics, Inc., Celgene Corp., BioNJ, Inc. y Nextpoint Therapeutics, Inc. Anteriormente, el Dr. Roden trabajó como Vicepresidente Senior y Jefe de Estrategia Empresarial en Bristol Myers Squibb Co., como Director Ejecutivo y Analista en UBS Securities LLC, como Analista en Merrill Lynch, Pierce, Fenner & Smith, Inc. (antigua), jefe de investigación de renta variable de biotecnología global en UBS Investment Bank (Nueva York), vicepresidente en JPMorgan Securities, Inc. y analista asociado en Credit Suisse Securities (USA) LLC (broker), así como asociado en Credit Suisse First Boston. Se licenció en la Universidad George Mason, se graduó en la Universidad de Georgetown y se doctoró en el Albert Einstein College of Medicine, Inc.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
AKTIS ONCOLOGY, INC. 0,17 % | 09/01/2026 | 91.998 ( 0,17 % ) | 2 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| AKTIS ONCOLOGY, INC. | Director Ejecutivo | 01/09/2020 |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Develops proprietary delivery technologies to unlock previously inaccessible cells | Director/Miembro de la Junta | 01/01/2023 |
MPM BioImpact LLC
 MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Inversor de Capital Privado | 01/08/2020 |
Orna Therapeutics, Inc.
 Orna Therapeutics, Inc. BiotechnologyHealth Technology Develops RNA therapeutics | Director/Miembro de la Junta | 01/05/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates life sciences research and development company | Director/Miembro de la Junta | 01/12/2024 |
| ITEOS THERAPEUTICS, INC. | Director/Miembro de la Junta | 03/02/2023 |
| TURMERIC ACQUISITION CORP. | Presidente | 01/12/2022 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2020 |
UBS Securities LLC
 UBS Securities LLC Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 01/05/2016 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 19 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Credit Suisse Securities (USA) LLC (Broker)
 Credit Suisse Securities (USA) LLC (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
Merrill Lynch, Pierce, Fenner & Smith, Inc. /Old/
 Merrill Lynch, Pierce, Fenner & Smith, Inc. /Old/ Investment Banks/BrokersFinance Provides brokerage services | Finance |
UBS Securities LLC
UBS Securities LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
JPMorgan Securities LLC
 JPMorgan Securities LLC Investment Banks/BrokersFinance Provides corporate, investment banking, consumer and commercial banking, asset management, payment & security solutions | Finance |
MPM BioImpact LLC
MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
George Mason University
 George Mason University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Georgetown University
 Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Credit Suisse Securities (USA) LLC
 Credit Suisse Securities (USA) LLC Regional BanksFinance Provides investment banking, asset management and securities brokerage services | Finance |
BioNJ, Inc.
 BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services Promotes the biotechnology industry in New Jersey | Commercial Services |
Albert Einstein College of Medicine, Inc.
 Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
iTeos Therapeutics, Inc.
 iTeos Therapeutics, Inc. BiotechnologyHealth Technology Develops immunomodulators for cancer treatments | Health Technology |
UBS Investment Bank (New York)
 UBS Investment Bank (New York) Financial ConglomeratesFinance Provides financial services | Finance |
Nextpoint Therapeutics, Inc.
Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates life sciences research and development company | Commercial Services |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Develops RNA therapeutics | Health Technology |
Turmeric Acquisition Corp.
 Turmeric Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Aktis Oncology, Inc.
 Aktis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops and discovers radiopharmaceuticals to treat tumor cancers | Health Technology |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Develops proprietary delivery technologies to unlock previously inaccessible cells | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
Elige MarketScreener 
